Heatwurx Inc. (NASDAQ:PCSA) Short Interest Update

Heatwurx Inc. (NASDAQ:PCSA) was the recipient of a large drop in short interest in August. As of August 14th, there was short interest totaling 67,319 shares, a drop of 68.8% from the July 30th total of 215,851 shares. Based on an average daily trading volume, of 78,571 shares, the short-interest ratio is currently 0.9 days. Currently, 2.5% of the shares of the stock are sold short.

Heatwurx Price Performance

Shares of Heatwurx stock traded down $0.05 during trading on Friday, hitting $2.06. 9,591 shares of the stock were exchanged, compared to its average volume of 77,958. Heatwurx has a 12-month low of $1.67 and a 12-month high of $14.24. The stock has a market cap of $5.71 million, a price-to-earnings ratio of -0.49 and a beta of 0.99. The firm’s 50-day moving average price is $2.22 and its 200 day moving average price is $2.46.

Heatwurx (NASDAQ:PCSA) last released its quarterly earnings results on Friday, August 14th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.19).

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heatwurx in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.00.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.